achieving
clinical remission on medication - as the sufficient response (otherwise - as the insufficient
Nouwen, A.,
Deschenes, S.S.,
Balkhiyarova, Z.,
Albertorio-Diaz, J.R.,
Prokopenko, I.,
Schmitz, N. (2021) slightly better fit, the one-factor solution is more parsimonious. Depending on research or
clinical needs
is the only method to
clinically treat CE dysfunction; however, this treatment strategy faces
Nadyrshina, D.,
Zaripova, A.,
Tyurin, A.,
Minniakhmetov, I.,
Zakharova, E.,
Khusainova, R. (2022) in FGF23; c.-14C>T in IFITM5 and c.1903C>T, p. Arg635* in LAMB3) in 4 patients with typical OI
clinicYang, L.,
Luo, W.,
Zhang, Q,
Hong, S.,
Wang, Y.,
Samorodov, A.V.,
Chattipakorn, N.,
Pavlov, V.N.,
Liang, G. (2021) no pharmacological therapy in
clinic. Accumulating evidence has demonstrated that natural compounds from herbs have
of lncRNAs in cancer and their potential
clinical applications as diagnostic biomarkers and therapeutic
KHABIBOV, M.,
GARIFULLIN, A.,
KHAMITOV, F.,
KHALIKOVA, L.,
BOUMBER, Y.,
KHADDOUR, K.,
FERNANDEZ, M.,
KUZNETSOVA, N.,
KIT, O.,
KHARIN, L. (2022) and is associated with a poor
clinical prognosis. Despite the progress in the understanding of the
molecular
Ivanova, E.,
Gilyazova, I.,
Pavlov, V.,
Izmailov, A.,
Gimalova, G.,
Karunas, A.,
Prokopenko, I.,
Khusnutdinova, E. (2022) variants, located in microRNA biogenesis genes, in 464 individuals with
clinically diagnosed ccRCC and 1042
Lu, Enzhou,
Gareev, Ilgiz,
Yuan, Chao,
Liang, Yanchao,
Sun, Jingxian,
Chen, Xin,
Beylerli, Ozal,
Sufianov, Albert,
Zhao, Shiguang,
Yang, Guang (2022) in
clinical practice. Chemotherapy with platinum drugs such as cisplatin, carboplatin, oxaliplatin, or a
Zheng, BJ,
Wang, CL;,
Yao, JB;,
Zhu, SY;,
Meshcheryakova, S;,
Shi, HZ (2022) Drainage Catheter Placement Technique between July 2019 and June 2021.
Epidemiological,
clinical